Stocks
Atara Biotherapeutics Financial Statements (ATRA) |
||||||||||
| Atara Biotherapeuticssmart-lab.ru | % | 2019 | 2020 | 2021 | 2022 | 2023 | LTM ? | |||
|---|---|---|---|---|---|---|---|---|---|---|
| Report date | 27.02.2020 | 01.03.2021 | 28.02.2022 | 08.02.2023 | 28.03.2024 | 12.11.2024 | ||||
| Currency | USD | USD | USD | USD | USD | USD | ||||
| Financial report URL | ||||||||||
| Revenue, bln rub | ? | 0.000 | 0.000 | 20.3 | 63.6 | 8.57 | 100.4 | |||
| Operating Income, bln rub | -295.7 | -309.1 | -340.5 | -280.5 | -276.0 | -119.8 | ||||
| EBITDA, bln rub | ? | -282.9 | -296.7 | -331.1 | -213.7 | -266.0 | -125.5 | |||
| Net profit, bln rub | ? | -2 910 | -3 066 | -3 401 | -2 283 | -276.1 | -963.0 | |||
| OCF, bln rub | ? | -235.6 | -180.8 | -220.5 | -270.4 | -193.0 | -94.7 | |||
| CAPEX, bln rub | ? | 5.73 | 4.51 | 10.6 | 4.19 | 1.22 | 0.200 | |||
| FCF, bln rub | ? | -241.4 | -185.3 | -231.1 | -274.6 | -194.2 | -94.9 | |||
| Dividend payout, bln rub | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | ||||
| Ordinary share dividend yield, % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | ||||
| Dividend payout ratio, % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0 | ||||
| OPEX, bln rub | 295.7 | 309.1 | 360.8 | 344.1 | 275.7 | 202.8 | ||||
| Cost of production, bln rub | 8.11 | 9.87 | 11.4 | 14.6 | 8.89 | 17.4 | ||||
| R&D, bln rub | 216.1 | 244.7 | 282.0 | 272.5 | 224.8 | 163.3 | ||||
| Interest expenses, bln rub | 0.000 | 0.000 | 0.000 | 1.99 | 5.29 | 4.77 | ||||
| Assets, bln rub | 342.9 | 588.1 | 468.1 | 376.4 | 165.5 | 142.7 | ||||
| Net Assets, bln rub | ? | 290.8 | 462.3 | 279.6 | 126.6 | -99.2 | -90.5 | |||
| Debt, bln rub | 14.1 | 13.0 | 25.5 | 71.7 | 57.9 | 35.2 | ||||
| Cash, bln rub | 259.1 | 500.7 | 371.1 | 242.8 | 51.7 | 67.2 | ||||
| Net debt, bln rub | -245.0 | -487.6 | -345.6 | -171.1 | 6.15 | -31.9 | ||||
| Ordinary share price, rub | 411.8 | 490.8 | 394.0 | 82.0 | 12.8 | 1.20 | ||||
| Number of ordinary shares, mln | 2.05 | 2.96 | 3.75 | 4.08 | 4.24 | 7.47 | ||||
| Market cap, bln rub | 845 | 1 452 | 1 476 | 335 | 54 | 9 | ||||
| EV, bln rub | ? | 600 | 964 | 1 131 | 163 | 60 | -23 | |||
| Book value, bln rub | 291 | 462 | 280 | 127 | -99 | -91 | ||||
| EPS, rub | ? | -1 418 | -1 036 | -907.8 | -559.6 | -65.2 | -129.0 | |||
| FCF/share, rub | -117.6 | -62.6 | -61.7 | -67.3 | -45.8 | -12.7 | ||||
| BV/share, rub | 141.7 | 156.3 | 74.6 | 31.0 | -23.4 | -12.1 | ||||
| EBITDA margin, % | ? | -1 628% | -336.2% | -3 103% | -124.9% | |||||
| Net margin, % | ? | -16 723% | -3 591% | -3 221% | -958.8% | |||||
| FCF yield, % | ? | -28.6% | -12.8% | -15.7% | -82.1% | -357.6% | -1 059% | |||
| ROE, % | ? | -1 001% | -663.2% | -1 216% | -1 803% | 278.3% | 1 064% | |||
| ROA, % | ? | -848.5% | -521.4% | -726.6% | -606.5% | -166.8% | -674.8% | |||
| P/E | ? | -0.29 | -0.47 | -0.43 | -0.15 | -0.20 | -0.01 | |||
| P/FCF | -3.50 | -7.84 | -6.39 | -1.22 | -0.28 | -0.09 | ||||
| P/S | ? | 72.6 | 5.26 | 6.34 | 0.09 | |||||
| P/BV | ? | 2.91 | 3.14 | 5.28 | 2.64 | -0.55 | -0.10 | |||
| EV/EBITDA | ? | -2.12 | -3.25 | -3.41 | -0.76 | -0.23 | 0.18 | |||
| Debt/EBITDA | 0.87 | 1.64 | 1.04 | 0.80 | -0.02 | 0.25 | ||||
| R&D/CAPEX, % | 3 769% | 5 421% | 2 665% | 6 500% | 18 380% | 81 675% | ||||
| CAPEX/Revenue, % | 52.0% | 6.60% | 14.3% | 0.20% | ||||||
| Atara Biotherapeutics shareholders | ||||||||||
